

Resource Summary Report

Generated by [dkNET](#) on Sep 4, 2026

A-673

RRID:CVCL_0080

Type: Cell Line

Proper Citation

RRID:CVCL_0080

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0080

Proper Citation: RRID:CVCL_0080

Description: Cell line A-673 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Ewing sarcoma

Defining Citation: [PMID:212188](#), [PMID:327080](#), [PMID:375235](#), [PMID:3335022](#), [PMID:4357758](#), [PMID:6173755](#), [PMID:6256643](#), [PMID:6825208](#), [PMID:6954533](#), [PMID:8275086](#), [PMID:8378080](#), [PMID:10379870](#), [PMID:11423975](#), [PMID:12068308](#), [PMID:12606131](#), [PMID:14697648](#), [PMID:16888811](#), [PMID:17431109](#), [PMID:19787792](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:21822310](#), [PMID:22142829](#), [PMID:22282976](#), [PMID:22460905](#), [PMID:23882450](#), [PMID:24312454](#), [PMID:24758355](#), [PMID:25010205](#), [PMID:25223734](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26351324](#), [PMID:26428435](#), [PMID:26589293](#), [PMID:26979953](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30879952](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:34413129](#), [PMID:35839778](#), [PMID:36476851](#)

Comments: Population: Caucasian., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: MD Anderson Cell Lines Project., Part of: Ewing Sarcoma Cell Line Atlas (ESCLA)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Problematic cell line: Misclassified. Originally thought to be a rhabdomyosarcoma cell line but shown to be from an Ewing sarcoma (PubMed=10379870; PubMed=12606131; PubMed=14697648)..

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: A-673

Synonyms: A673, RMS 1598, RMS1598

Cross References: BTO:BTO_0003768, CLO:CLO_0001605, CLO:CLO_0001606, EFO:EFO_0002106, CLDB:cl166, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-1598, ATCC:CRL-7910, BioGRID_ORCS_Cell_line:160, BioSample:SAMN03473282, BioSample:SAMN10987881, cancercellines:CVCL_0080, CCRID:3101HUMTCHu223, Cell_Model_Passport:SIDM00848, ChEMBL-Cells:ChEMBL3307384, ChEMBL-Targets:ChEMBL614517, CLS:300454, Cosmic:684052, Cosmic:1091064, Cosmic:1097757, Cosmic:1388901, Cosmic:1718108, Cosmic:1995338, Cosmic:2228213, Cosmic:2250469, Cosmic:2294580, Cosmic-CLP:684052, DepMap:ACH-000052, ECACC:85111504, EGA:EGAS00001000610, EGA:EGAS00001000978, ENCODE:ENCBS304EKV, ENCODE:ENCBS385OLC, ENCODE:ENCBS615MBV, ENCODE:ENCBS790NPQ, GDSC:684052, GEO:GSM510002, GEO:GSM827304, GEO:GSM886859, GEO:GSM887924, GEO:GSM1669590, GEO:GSM1676306, GEO:GSM1701623, GEO:GSM1899422, GEO:GSM5359628, GEO:GSM5359629, GEO:GSM5359630, GEO:GSM5359631, GEO:GSM5359632, GEO:GSM5359633, GEO:GSM5362876, GEO:GSM5362877, GEO:GSM5362878, GEO:GSM5362879, GEO:GSM5362880, GEO:GSM5362881, GEO:GSM5363936, GEO:GSM5363937, GEO:GSM5363938, GEO:GSM5363939, GEO:GSM5363940, IARC_TP53:705, IARC_TP53:21168, IGRhCellID:A673, KCLB:21598, LiGeA:CCLE_182, LINCX_LDP:LCL-1410, Lonza:1455, PharmacDB:A673_49_2019, PRIDE:PX030304, Progenetix:CVCL_0080, PubChem_Cell_line:CVCL_0080, Wikidata:Q54606055

ID: CVCL_0080

Record Creation Time: 20220427T215104+0000

Record Last Update: 20260904T021129+0000

Ratings and Alerts

No rating or validation information has been found for A-673.

Warning: Problematic cell line: Misclassified. Originally thought to be a rhabdomyosarcoma cell line but shown to be from an Ewing sarcoma (PubMed=10379870; PubMed=12606131; PubMed=14697648).

Population: Caucasian., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: MD Anderson Cell Lines Project., Part of: Ewing Sarcoma Cell Line Atlas (ESCLA)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Problematic cell line: Misclassified. Originally thought to be a rhabdomyosarcoma cell line but shown to be from an Ewing sarcoma (PubMed=10379870; PubMed=12606131; PubMed=14697648).. **Warning:** Discontinued: ATCC; CRL-7910

Population: Caucasian., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: MD Anderson Cell Lines Project., Part of: Ewing Sarcoma Cell Line Atlas (ESCLA)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).,

Problematic cell line: Misclassified. Originally thought to be a rhabdomyosarcoma cell line but shown to be from an Ewing sarcoma (PubMed=10379870; PubMed=12606131; PubMed=14697648)..

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 276 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Ji YR, et al. (2026) Detection of Extracellular Vesicles with Colocalized Surface Markers via a Capture-Release-Capture Strategy for Treatment Monitoring in Ewing Sarcoma. *Advanced healthcare materials*, 15(18), e05917.

Gracilla DE, et al. (2026) FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy. *Cancer research*, 86(11), 2660.

Downing NF, et al. (2026) PRC2/FOXO1-Mediated Repression Determines Interchangeability of ETS Oncogenes in Prostate Cancer and Ewing Sarcoma. *Molecular cancer research : MCR*, 24(1), 48.

Milovanovi? D, et al. (2026) Tissue-specific restriction of transposon-derived regulatory elements safeguards cell-type identity. *Cell reports*, 45(1), 116817.

Suresh V, et al. (2026) Modelling EWS::FLI1 protein fluctuations reveal determinants of tumor plasticity in Ewing sarcoma. *EMBO molecular medicine*, 18(2), 646.

Dreher RD, et al. (2026) LSD1 Performs Demethylase-Independent and Context-Specific Roles in Ewing Sarcoma. *Cancer research communications*, 6(3), 585.

Burke CM, et al. (2026) Antitumor Activity of Trastuzumab Deruxtecan in Pediatric Solid Tumors with Variable HER2 Expression. *Molecular cancer therapeutics*, 25(1), 156.

Porazzi P, et al. (2025) EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models. *Cancer cell*, 43(3), 537.

Ziener J, et al. (2025) Combined inhibition of ribonucleotide reductase and WEE1 induces synergistic anticancer activity in Ewing's sarcoma cells. *BMC cancer*, 25(1), 277.

Rask GC, et al. (2025) Seclidemstat (SP-2577) Induces Transcriptomic Reprogramming and Cytotoxicity in Multiple Fusion-Positive Sarcomas. *Cancer research communications*, 5(9), 1584.

Dreher RD, et al. (2025) LSD1 Performs Demethylase-Independent and Context-Specific Roles in Ewing Sarcoma. *bioRxiv : the preprint server for biology*.

Figuerola-Bou E, et al. (2025) KDM6 Demethylases Contribute to EWSR1::FLI1-Driven Oncogenic Reprogramming in Ewing Sarcoma. *Cancer research*, 85(22), 4485.

Noorizadeh R, et al. (2025) YAP1 is a key regulator of EWS::FLI1-dependent malignant transformation upon IGF-1-mediated reprogramming of bone mesenchymal stem cells. *Cell reports*, 44(3), 115381.

Chicón-Bosch M, et al. (2025) Multi-omics profiling reveals key factors involved in Ewing sarcoma metastasis. *Molecular oncology*, 19(4), 1002.

Berger HR, et al. (2025) Endoglin-Directed CAR T Cells Comprehensively Target Tumors in Advanced Sarcomas. *Cancer immunology research*, 13(10), 1591.

Ceranski AK, et al. (2025) Refined culture conditions with increased physiological relevance uncover oncogene-dependent metabolic signatures in Ewing sarcoma spheroids. *Cell reports methods*, 5(2), 100966.

Manara MC, et al. (2024) Engagement of CD99 Activates Distinct Programs in Ewing Sarcoma and Macrophages. *Cancer immunology research*, 12(2), 247.

Graca Marques J, et al. (2024) The Chromatin Remodeler CHD4 Sustains Ewing Sarcoma Cell Survival by Controlling Global Chromatin Architecture. *Cancer research*, 84(2), 241.

Pezzella M, et al. (2024) Tumor-derived G-CSF induces an immunosuppressive microenvironment in an osteosarcoma model, reducing response to CAR.GD2 T-cells. *Journal of hematology & oncology*, 17(1), 127.

Suvarna K, et al. (2024) Ceramide-induced cleavage of GPR64 intracellular domain drives Ewing sarcoma. *Cell reports*, 43(8), 114497.